<DOC>
	<DOCNO>NCT01226680</DOCNO>
	<brief_summary>This phase 2 study evaluate safety efficacy tasocitinib ( CP-690,550 ) subject moderate severe dry eye disease . Both subjective objective clinical endpoint measure duration 12-week treatment .</brief_summary>
	<brief_title>A Study Of Tasocitinib In Dry Eye Subjects</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Males female age 18 year old time consent Diagnosis dry eye disease , characterize subjective symptom dry eye least 6 month , Schirmer test without anesthesia : = &gt; 1 mm = &lt; 7 mm , sum corneal fluorescein stain score = &gt; 4 ( NEI Scale ) , subject grade total score = &gt; 23 OSDI Planned initiation , change , concomitant medication could affect dry eye within 30 day Screening visit study Ocular disorder may confound interpretation study result significant corneal surface disease cause dry eye , abnormal corneal sensitivity , abnormal tear spreading , include limited following : abnormal lid function , lid position , blink rate , opinion investigator clinically significant , history herpetic keratopathy Lacrimal punctal occlusion ( plugs cautery ) within 2 month Screening visit Contact lens wear within 2 week Screening visit and/or study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Dry Eye</keyword>
	<keyword>Schirmer test</keyword>
	<keyword>corneal stain</keyword>
	<keyword>OSDI</keyword>
	<keyword>OCI</keyword>
</DOC>